Nuwellis, Inc. — fact timeline

Michael McCormick was appointed as Member of the Board of Directors at Nuwellis, Inc..

“Effective as of June 30, 2026, the Board appointed Michael McCormick as the Company’s Chief Executive Officer and President and member of the Company’s board of directors.”

Michael McCormick was appointed as Chief Executive Officer and President at Nuwellis, Inc..

“Effective as of June 30, 2026, the Board appointed Michael McCormick as the Company’s Chief Executive Officer and President and member of the Company’s board of directors.”

John L. Erb resigned as President and Chief Executive Officer at Nuwellis, Inc..

“On June 16, 2026, Nuwellis, Inc. (the “Company” ) announced that John L. Erb resigned from the Company, effective June 30, 2026 (“ Resignation Date ”).”

Nuwellis, Inc. reported the first quarter ended March 31, 2026 results: revenue $2.4 million, net income approximately $4.3 million.

“for patients with cardiorenal conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter and Recent Highlights: • Net sales were $2.4 million, a 26% increase compared to the prior-year period • Gross margin improved to 70.1%, reflecting improved pricing, product mix, and the transition to contract manufacturing •”

Nuwellis, Inc. reported the full year ended December 31, 2025 results: revenue $8.3 million, net income $17.5 million.

“Revenue for the full year ended December 31, 2025, was $8.3 million, a 5% decrease compared to the prior year.”

Nuwellis, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2.4 million, net income approximately $2.4 million.

“conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: • Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially. • 208% increase in U.S. console sales in Q4 versus prior year quarter. • Heart Failure revenue”

Nuwellis, Inc. issued January Inducement Warrants of warrant to certain investors.

“the Company offered and sold the Securities and January Inducement Warrants in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506 promulgated thereunder”

Nuwellis, Inc. issued 1,989,074 Common Warrant Shares of common stock to a certain institutional accredited investor for combined purchase price of $3.09.

“of Common Stock (the “ Common Warrant Shares ” and together with the Pre-Funded Warrant Shares and the Pre-Funded Warrants, the “ Securities ”) for a combined purchase price of $3.09. Under the terms of the Pre-Funded Warrants and Common Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant or Common Warrant, if, upon”

Nuwellis, Inc. issued 994,537 Pre-Funded Warrant Shares of common stock to a certain institutional accredited investor for combined purchase price of $3.09.

“of Common Stock (the “ Common Warrant Shares ” and together with the Pre-Funded Warrant Shares and the Pre-Funded Warrants, the “ Securities ”) for a combined purchase price of $3.09. Under the terms of the Pre-Funded Warrants and Common Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant or Common Warrant, if, upon”

Nuwellis, Inc. issued 1,989,074 common warrants of warrant to a certain institutional accredited investor for combined purchase price of $3.09.

“of Common Stock (the “ Common Warrant Shares ” and together with the Pre-Funded Warrant Shares and the Pre-Funded Warrants, the “ Securities ”) for a combined purchase price of $3.09. Under the terms of the Pre-Funded Warrants and Common Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant or Common Warrant, if, upon”

Nuwellis, Inc. issued 994,537 pre-funded common stock purchase warrants of warrant to a certain institutional accredited investor for combined purchase price of $3.09.

“of Common Stock (the “ Common Warrant Shares ” and together with the Pre-Funded Warrant Shares and the Pre-Funded Warrants, the “ Securities ”) for a combined purchase price of $3.09. Under the terms of the Pre-Funded Warrants and Common Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant or Common Warrant, if, upon”

Nuwellis, Inc. entered into Private Placement Purchase Agreement with a certain institutional accredited investor valued at combined purchase price of $3.09 (effective 2026-01-29).

“On January 29, 2026, Nuwellis, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Private Placement Purchase Agreement ”) with a certain institutional accredited investor (the “ Purchaser ”) in connection with a private placement (the “ Private Placement ”) for the offer, issuance and sale of (i) 994,537 pre-funded common stock purchase warrants (the “ Pre-Funded Warrants ”) to purchase up to 994,537 shares (the “ Pre-Funded Warrant Shares ”) of the Company’s common stock, $0.0001 par value (the “ Common Stock ”) and (ii) 1,989,074 common warrants (the “ Common Warrants ”, and together with the Pre-Funded Warrants, the “ Private Placement Warrants ”) to purchase up to 1,989,074 shares of Common Stock (the “ Common Warrant Shares ” and together with the Pre-Funded Warrant Shares and the Pre-Funded Warrants, the “ Securities ”) for a combined purchase price of $3.09.”

Nuwellis, Inc.: Amended certificate of incorporation to effect a 1-for-42 reverse stock split (effective 2025-07-02).

“On July 2, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.”

Nuwellis, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 18, 2025, Nuwellis, Inc. (the “Company” ) received a letter (the “Deficiency Notice” ) from the Listing Qualifications Department (the “Staff” ) of the Nasdaq Stock Market ( “Nasdaq” ) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement” ). The Deficiency Notice also indicated th”

Nuwellis, Inc.: Filed Certificate of Designation for Series F-1 Convertible Preferred Stock, authorizing 100 shares with a 19.99% beneficial ownership limitation upon conversion (effective 2025-06-06).

“On June 6, 2025, Nuwellis, Inc. (the “Company”) filed the Certificate of Designation of Preferences, Rights and Limitations of Series F-1 Convertible Preferred Stock (the “F-1 Certificate of Designation”) with the Secretary of State of the State of Delaware, authorizing the issuance of 100 shares of Series F-1 Convertible Preferred Stock (the “Series F-1 Stock”).”

John L. Erb was appointed as Interim Chief Executive Officer and President at Nuwellis, Inc..

“the Board appointed John L. Erb as the Company’s Interim Chief Executive Officer and President.”

Nestor Jaramillo Jr. departed as President and Chief Executive Officer at Nuwellis, Inc..

“Nestor Jaramillo, Jr. is retiring from the Company, effective February 18, 2025”

Nuwellis, Inc. reported the first quarter ended March 31, 2024 results: revenue $1.9 million, net income $3.8 million, EPS a loss of $0.60 per basic and diluted common share.

“company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024. Highlights: • Revenue of $1.9 million, a 2% increase over the prior-year period. • Consumables sales, representing 82% of total revenue, grew 11% year-over-year. • Pediatric revenue growth of 40% year over year led”

Nuwellis, Inc. entered into Warrant Agency Agreement with Equiniti Trust Company, LLC (effective 2024-04-30).

“On April 30, 2024, the Company also entered into a Warrant Agency Agreement with the Company’s transfer agent, Equiniti Trust Company, LLC, who will act as warrant agent for the Company, setting forth the terms and conditions of the Common Warrants sold in this Offering (the “ Warrant Agency Agreement ”).”

Nuwellis, Inc. entered into Securities Purchase Agreement with certain of the purchasers in the Offering (effective 2024-04-26).

“On April 26, 2024, the Company entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain of the purchasers in the Offering.”

Nuwellis, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC (effective 2024-04-26).

“On April 26, 2024, Nuwellis, Inc. (the “ Company ”) entered into a Placement Agency Agreement (the “ Placement Agency Agreement ”) with Roth Capital Partners, LLC (the “ Placement Agent ”), pursuant to which the Company issued and sold, in a best efforts registered public offering by the Company (the “ Offering ”), 8,419,996 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) , pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 2,830,004 shares of common stock and common warrants (the “ Common Warrants ) to purchase up to an aggregate of 16,875,000 shares of its common stock.”

Nuwellis, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $2.6 million, net income net loss attributable to common shareholders of $7.9 million, EPS loss of $2.24 per basic and diluted common share.

“the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2023. Highlights: ● Record quarter revenue of $2.6 million, a 9% increase over prior-year period. Full year revenue of $8.9 million, a 4% increase over 2022. ● Fourth quarter pediatric revenue grew 35% year over year; 28% increase in”

Nuwellis, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 7, 2023, Nuwellis, Inc. (the “Company” ) received a letter (the “Notice” ) from the Listing Qualifications Department (the “Staff” ) of the Nasdaq Stock Market ( “Nasdaq” ) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement” ). In accordance with Nasdaq Marketplace Rule 581”

Nuwellis, Inc. reported the third quarter ended September 30, 2023 results: revenue $2.4 million, net income $3.4 million, EPS a loss of $1.81 per share.

“company dedicated to transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2023. • Revenue of $2.4 million for the third quarter 2023, increased 16% over the prior quarter and increased 17% over the prior-year period. • Therapy utilization, or the number of circuits per placed”

David McDonald was appointed as Director at Nuwellis, Inc..

“the appointment of David McDonald to its Board”

Archelle Georgiou was appointed as Director at Nuwellis, Inc..

“the appointment of Archelle Georgiou (Feldshon) , M.D. to its Board”

Nuwellis, Inc.: Filed Certificate of Designation for Series J Convertible Redeemable Preferred Stock (effective 2023-10-16).

“On October 16, 2023, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware to establish the powers, preferences and rights of the shares of the Series J Convertible Preferred Stock and the qualifications, limitations or restrictions thereof.”

Nuwellis, Inc. entered into Placement Agency Agreement with Lake Street Capital Markets, LLC and Maxim Group LLC valued at Issuance and sale of Units consisting of Series J Convertible Preferred Stock and Warrants, gross pr (effective 2023-10-12).

“On October 12, 2023, Nuwellis, Inc. (the “ Company ”) entered into a Placement Agency Agreement (the “ Placement Agency Agreement ”) with Lake Street Capital Markets, LLC and Maxim Group LLC (the “ Placement Agents ”), pursuant to which the Company issued and sold, in a best efforts registered public offering by the Company (the “ Offering ”), 150,000 units (each a “ Unit ” and collectively, the “ Units ”), with each Unit consisting of (A) one share of the Company’s Series J Convertible Redeemable Preferred Stock, par value $0.0001 per share (the “ Series J Convertible Preferred Stock ”), and (B) one warrant (each, a “ Warrant ” and collectively, the “ Warrants ”) to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock, at a price to the public of $15.00 per Unit, less placement agent fees and commissions.”

Robert B. Scott was appointed as Chief Financial Officer at Nuwellis, Inc..

“Robert B. Scott will be appointed as Chief Financial Officer of Nuwellis, Inc.”

Nuwellis, Inc. reported second quarter ended June 30, 2023 results: revenue $2.1 million, net income $4.8 million, EPS $3.65 per share.

“Revenue for the second quarter of 2023 was $2.1 million, compared to $2.2 million in the prior-year period. Results in the quarter were driven by an increase of 14% in circuit sales offset by lower console sales. Gross margin was 55.3% for the second quarter of 2023, a 730-basis point improvement year over year, primarily due to favorable product sales mix and a $0.1 million non-cash inventory write-off related to the discontinuation of a distribution agreement in the prior-year period. Selling, general and administrative expenses for the second quarter of 2023 were $4.7 million, compared to $4.3 million in the prior-year period. The increase was primarily due to increased professional fees in the current year quarter. Second quarter research and development expenses were $1.5 million, compared to $1.1 million in the second quarter of 2022, reflecting higher spend on the new pediatric CRRT device as we ramp up the development effort in preparation for the IDE submission. Total operatin”

Rob Scott was appointed as Chief Financial Officer at Nuwellis, Inc..

“The Company intends to appoint Rob Scott, the Company’s current Senior Finance Director, as its new Chief Financial Officer, effective September 2, 2023.”

Lynn Blake resigned as Chief Financial Officer at Nuwellis, Inc..

“On August 4, 2023, Lynn Blake notified Nuwellis, Inc., a Delaware corporation (the “ Company ”) of her decision to resign as the Chief Financial Officer of the Company.”

Nuwellis, Inc. entered into Registration Rights Agreement with DaVita Inc. valued at Company agreed to register the resale of the shares of Common Stock issuable upon exercise of the Wa (effective 2023-06-19).

“Concurrent with the signing of the Supply Agreement and Warrant, the Company entered into a Registration Rights Agreement (“ Registration Rights Agreement ”) with DaVita, whereby the Company agreed, subject to DaVita’s delivery of the Ultrafiltration Services Approval, to register the resale of the shares of Common Stock issuable upon exercise of the Warrant (“ Underlying Shares ”) on a Form S-1 or Form S-3, if eligible, upon DaVita’s demand.”

Nuwellis, Inc. entered into Common Stock Warrant Agreement with DaVita Inc. valued at warrant to purchase up to an aggregate of 1,289,081 shares of common stock at an exercise price of $ (effective 2023-06-19).

“In conjunction with the Supply Agreement, the Company issued DaVita a warrant to purchase up to an aggregate of 1,289,081 shares of common stock of the Company, par value $0.0001 per share, at an exercise price of $3.2996 per share, provided that at no time can it be exercised for an amount of shares that would represent greater than 19.9% ownership in the Company (the “ Warrant ”) subject to certain vesting milestones.”

Nuwellis, Inc. entered into Supply and Collaboration Agreement with DaVita Inc. valued at DaVita will pilot the Aquadex ultrafiltration therapy system to treat adult patients with congestive (effective 2023-06-19).

“On June 19, 2023, Nuwellis, Inc. (the “ Company ”) entered into a Supply and Collaboration Agreement (the “ Supply Agreement ”) with DaVita Inc., a Delaware corporation (“ DaVita ”), pursuant to which DaVita will pilot the Aquadex ultrafiltration therapy system to treat adult patients with congestive heart failure and related conditions within select U.S. markets .”

Michael McCormick was appointed as Lead Independent Director at Nuwellis, Inc..

“On May 30, 2023, the Board of Directors (the " Board ") of Nuwellis, Inc., a Delaware corporation (the " Company ") approved, effective as of June 1, 2023, the appointment of Michael McCormick to fill a vacancy in the Board.”

Nuwellis, Inc. shareholders approved Ratification of Baker Tilly US, LLP as independent registered public accounting firm for 2023 at the 2023-05-19 meeting.

“Proposal 2—Advisory Approval of Independent Registered Public Accounting Firm for 2023 Votes For Votes Against Votes Abstain 501,368 27,443 3,255”

Nuwellis, Inc. shareholders approved Election of Class I Directors at the 2023-05-19 meeting.

“Proposal 1 — Election of Directors Class III Nominees Votes For Votes Withheld Broker Non-Votes Nestor Jaramillo, Jr. 94,426 38,338 399,302 Warren Watson 95,208 37,556 399,302”

Nuwellis, Inc. reported the first quarter ended March 31, 2023 results: revenue $1.8 million, net income $6.5 million, EPS a loss of $5.76 per basic and diluted common share.

“technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2023. • Revenue of $1.8 million for the first quarter 2023, a 5% decrease over the prior-year period. • By segment, first quarter 2023 revenue in Heart Failure increased approximately 21% over the same period”

Nuwellis, Inc. reported the twelve months ended December 31, 2022 results: revenue $8.5 million.

“Full year revenue of $8.5 million, an 8% increase over 2021.”

Nuwellis, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $2.3 million, net income $1.9 million, EPS loss of $5.00 per basic and diluted common share.

“Revenue for the fourth quarter of 2022 was $2.3 million, compared to $1.6 million in the prior-year period. Gross margin was 56.9% for the fourth quarter of 2022, compared to 54.4% in the prior-year period, an increase of 250 basis points, resulting from increased sales volume. Selling, general and administrative expenses for the fourth quarter of 2022 were $4.7 million, compared to $4.1 million in the prior-year period. The increase in SG&A was primarily due to higher professional service fees and variable compensation expense, balanced with continued spending vigilance. Fourth quarter research and development expenses were $1.2 million, compared to $1.1 million in the fourth quarter of 2021, reflecting a slight increase in product development expenses . Net loss for the fourth quarter of 2022 was $1.9 million, or a loss of $5.00 per basic and diluted common share”

Steve Brandt resigned as Director at Nuwellis, Inc..

“On January 16, 2023, Mr. Steve Brandt provided notice of his resignation from the Board of Directors (the “Board”) of Nuwellis, Inc. (the “Company”), effective immediately.”

Nuwellis, Inc. reported the fourth quarter and full year 2022 results: revenue approximately $2.3 million and $8.5 million.

“preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be approximately $2.3 million and $8.5 million, respectively, representing an increase of 42% and 8% over the same periods last year. The fourth quarter growth rate reflects benefits from the Company’s”

Nuwellis, Inc. shareholders approved To authorize one or more adjournments of the stockholder meeting to solicit additional proxies in the event there are insufficient votes to approve the Warrant Proposal at the 2023-01-04 meeting.

“Proposal 2 - To authorize one or more adjournments of the stockholder meeting to solicit additional proxies in the event there are insufficient votes to approve the Warrant Proposal. VOTES FOR VOTES AGAINST ABSTAIN BROKER NON-VOTES 1,971,645 1,746,660 97,477 N/A”

Nuwellis, Inc. shareholders approved To approve pursuant to Nasdaq Listing Rule 5635(d) and Nasdaq’s interpretations and guidance thereunder, the issuance of up to 66,226,752 shares of the Company’s common stock upon exercise of warrants issued in the October 2022 Underwritten Offering at the 2023-01-04 meeting.

“Proposal 1 - To approve pursuant to Nasdaq Listing Rule 5635(d) and Nasdaq’s interpretations and guidance thereunder, the issuance of up to 66,226,752 shares of the Company’s common stock ( as the same is to be adjusted for the reverse stock split effectuated by the Company on December 9, 2022) upon the exercise of its warrants issued to investors in its underwritten offering that closed on October 18, 2022 (“ October 2022 Underwritten Offering ”) that may be equal to or exceed 20% of the Company’s common stock outstanding before the October 2022 Underwritten Offering (the “ Warrant Proposal ”). VOTES FOR VOTES AGAINST ABSTAIN BROKER NON-VOTES 1,955,994 1,791,220 68,568 N/A”

Nuwellis, Inc. entered into Distribution Agreement with SeaStar Medical Holding Corporation valued at upfront payment, milestone payments upon achievement of certain milestones and royalties on gross sa (effective 2022-12-27).

“On December 27, 2022, Nuwellis, Inc. (the “ Company ”) entered into a license and distribution agreement (the “ Distribution Agreement ”) with SeaStar Medical Holding Corporation (“ SeaStar ”), pursuant to which SeaStar appointed the Company as its exclusive distributor for the sale and distribution of SeaStar’s Selective Cytopheretic Device (“ SCD ”) product throughout the United States following the receipt by SeaStar from the United States Food and Drug Administration (“ FDA ”) of a written authorization to market such product for pediatric use pursuant to the Humanitarian Device Exemption application submitted by SeaStar. Pursuant to the Distribution Agreement, SeaStar will receive an upfront payment, milestone payments upon achievement of certain milestones and royalties on gross sales of the SCD product.”

Nuwellis, Inc.: Amended Certificate of Incorporation to effect a one-for-one hundred reverse stock split of common stock (effective 2022-12-09).

“On December 9, 2022, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.”

Nuwellis, Inc. shareholders approved To authorize one or more adjournments to solicit additional proxies at the 2022-12-05 meeting.

“Proposal 3- To authorize one or more adjournments of the Special Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 1 and 2: VOTES FOR VOTES AGAINST ABSTAIN BROKER NON-VOTES 17,825,554 1,833,621 17,423 N/A”

Nuwellis, Inc. shareholders approved To approve an amendment to the 2017 Equity Incentive Plan regarding the Incentive Stock Option Limit at the 2022-12-05 meeting.

“Proposal 2- To approve an amendment to the Company’s 2017 Equity Incentive Plan to provide that the Incentive Stock Option Limit set forth in Section 3(c) of the Company’s 2017 Equity Incentive Plan shall not be subject to adjustment pursuant to the applicable provisions of Section 9(a)(i) of the Company’s 2017 Equity Incentive Plan in connection with the reverse stock split effected by the Company on October 16, 2020 or the first reverse stock split effected by the Company following December 5, 2022: VOTES FOR VOTES AGAINST ABSTAIN BROKER NON-VOTES 10,357,447 2,132,484 20,549 7,166,118”

Nuwellis, Inc. shareholders approved To approve an amendment to effect a reverse stock split at a ratio in the range of 1-for-50 to 1-for-100 at the 2022-12-05 meeting.

“Proposal 1- To approve an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Company’s outstanding common stock at a ratio in the range of 1-for-50 to 1-for-100, to be determined at the discretion of the Company’s board of directors, whereby each outstanding 50 to 100 common shares would be combined, converted and changed into 1 share of the Company’s common stock, to enable the Company to comply with the Nasdaq Stock Market’s continued listing requirements: VOTES FOR VOTES AGAINST ABSTAIN BROKER NON-VOTES 17,599,486 2,064,550 12,562 N/A”